Clinical Trials Directory

Trials / Completed

CompletedNCT01174264

Evaluation of Food Effect on Pharmacokinetics of Vismodegib

Evaluation of Food Effect on Pharmacokinetics of GDC-0449, an Inhibitor of Hedgehog Signaling

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
63 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

This randomized clinical trial studies the effect of food on the pharmacokinetics of vismodegib. Studying the effects of meals on the absorption of vismodegib may help doctors prescribe correct doses and label the drug accurately.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the effect of prandial states on the pharmacokinetic parameters of GDC-0449 (vismodegib). II. To evaluate the effect of fat content of meals on the pharmacokinetic parameters of GDC-0449. SECONDARY OBJECTIVES: I. To evaluate the effect of prandial states and fat content of meals on the safety profile of GDC-0449. II. To describe any anticancer activities of GDC-0449. OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM I: Patients receive a single dose of vismodegib orally (PO) on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28. ARM II: Patients receive a single dose of vismodegib PO after eating a high fat meal. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28. ARM III: Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28. In all arms, treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.

Conditions

Interventions

TypeNameDescription
OTHERPharmacological StudyCorrelative studies
DRUGVismodegibGiven PO

Timeline

Start date
2009-10-01
Primary completion
2014-12-01
Completion
2014-12-01
First posted
2010-08-03
Last updated
2017-05-19
Results posted
2016-03-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01174264. Inclusion in this directory is not an endorsement.